News
During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...
When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...
15h
TipRanks on MSNNovo Nordisk’s Stock Soars Amid Strategic MovesNovo Nordisk ( ($NVO) ) has risen by 10.44%. Read on to learn why. Novo Nordisk has seen a notable 10.44% increase in its stock price over the ...
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...
The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results